Rebate Visibility for Outpatient & Infusion Centers
Outpatient and infusion centers administer some of the highest-cost therapies in healthcare — and most have only partial visibility into the rebate activity those drugs carry. VativoRx maps that opportunity and builds a process to manage it consistently.
Schedule a Discovery Call →Where Value Gets Missed
Specialty biologics, oncology agents, and IV immunotherapies can carry significant rebate eligibility. But in infusion environments, the picture is rarely clean. Billing runs through one system. Purchasing runs through another. GPO contracts add a third layer. And 340B eligibility — where it applies — creates exclusion complexity that most programs handle inconsistently.
Most centers know rebate opportunity exists somewhere in their claims. Few have the process to surface it consistently, exclude what doesn't qualify, and report on it in a way finance can use.
What a Structured Process Can Surface
For a growing outpatient infusion center managing high-cost specialty therapies, visibility into rebate activity was limited — claims were being processed through multiple channels without a unified view of eligibility or submission status.
After implementing a structured review process with VativoRx, the center gained claim-level visibility into rebate-eligible activity across its administered drug mix for the first time.
Across a defined review period, the engagement identified a meaningful volume of eligible claims that had not previously been captured through existing workflows.
How VativoRx Works in Infusion Environments
VativoRx applies a structured, claim-level review process built specifically for provider-administered drugs. The process is designed around how infusion environments actually operate — with GPO and 340B exclusions handled systematically from the start, not reviewed manually each cycle.
What This Helps Improve
- A clearer view of which administered therapies in your drug mix carry manufacturer rebate eligibility
- A single, consolidated view of rebate activity across your drug mix — no manual aggregation across billing and purchasing systems
- A clear audit trail behind every eligibility determination — structured to answer questions before they're asked
- A defined process your revenue cycle and operations teams can work from on a repeating cadence
Low-Lift Start
- Getting started requires a defined set of claim-level data — we provide the full specification before any exchange begins
- Your internal team's time commitment is front-loaded to the initial data transfer — after that, involvement is limited to reviewing reporting outputs
- Ongoing cadence runs on defined inputs — minimal internal resources beyond periodic reporting review